Form 4: Bio-Rad Laboratories Executive Michael Crowley Reports Stock Transactions
SEC Form 4
EVP Michael Crowley reports the acquisition of Bio-Rad Class A common stock through vesting of restricted stock units and subsequent disposal to cover tax obligations.
Summary
- Michael Crowley, EVP of Global Commercial Operations at Bio-Rad Laboratories, reported several transactions involving Bio-Rad Class A common stock.
- These transactions occurred between September 1, 2024, and September 3, 2024.
- The transactions involved the acquisition of shares through the vesting of restricted stock units (RSUs) and the subsequent disposal of shares to satisfy tax withholding obligations.
- Specifically, Crowley acquired a total of 2,667 shares of Class A common stock through the vesting of RSUs.
- Simultaneously, Crowley disposed of a total of 1,069 shares to cover tax liabilities at a price of $337.32 on September 1st and 283 shares at $334.31 on September 3rd.
- Following these transactions, Crowley directly owns 8,171 shares of Bio-Rad Class A common stock and holds derivative securities (Restricted Stock Units) for 0 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and tax obligations, with no indication of unusual or concerning activity.
Positives
- The vesting of restricted stock units suggests that Crowley is meeting performance or time-based milestones set by the company.
- Crowley maintains a significant direct ownership stake in Bio-Rad, indicating alignment with shareholder interests.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies like Bio-Rad Laboratories and are comparable to similar filings made by executives at companies like Danaher, Thermo Fisher Scientific, and Agilent Technologies.
- The vesting schedules of the restricted stock units are typical, with annual installments being a common approach to incentivize long-term performance and retention.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation practices.
- Transparency through Form 4 filings helps maintain investor confidence.
Key Dates
| Date | Description |
|---|---|
| 09/03/2019 | Date of grant for 2,784 restricted stock units, vesting in five equal annual installments. |
| 09/02/2020 | Date of grant for 1,733 restricted stock units, vesting in four equal annual installments. |
| 09/01/2021 | Date of grant for 1,621 restricted stock units, vesting in four equal annual installments. |
| 09/01/2022 | Date of grant for 2,082 restricted stock units, vesting in four equal annual installments. |
| 09/01/2023 | Date of grant for 3,005 restricted stock units, vesting in four equal annual installments. |
| 09/01/2024 | Earliest transaction date reported; vesting of RSUs and disposal of shares for tax obligations. |
| 09/03/2024 | Latest transaction date reported; vesting of RSUs and disposal of shares for tax obligations. |
| 09/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.